Unique ID issued by UMIN | UMIN000000686 |
---|---|
Receipt number | R000000823 |
Scientific Title | A phase II study of preoperative S-1 plus Paclitaxel combination therapy and postoperative Paclitaxel followed by S-1 therapy for type 4 gastric cancer (OGSG 0502) |
Date of disclosure of the study information | 2007/04/23 |
Last modified on | 2021/11/15 22:56:59 |
A phase II study of preoperative S-1 plus Paclitaxel combination therapy and postoperative Paclitaxel followed by S-1 therapy for type 4 gastric cancer (OGSG 0502)
OGSG 0502
A phase II study of preoperative S-1 plus Paclitaxel combination therapy and postoperative Paclitaxel followed by S-1 therapy for type 4 gastric cancer (OGSG 0502)
OGSG 0502
Japan |
For patients with type 4 gastric cancer
Gastroenterology | Hematology and clinical oncology | Gastrointestinal surgery |
Malignancy
NO
For patients with type 4 gastric cancer which is resectable, a preoperative S-1 plus Paclitaxel combination therapy and postoperative Paclitaxel followed by S-1 therapy is evaluated on its response or feasibility.
Safety,Efficacy
Confirmatory
Pragmatic
Phase II
"The ratio of the patients who completed the regimen
The ratio of administered dose to the planed dose."
Response Rate
Overall Survival
Disease Free Survival
Histological CR
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
Treatment Methods
A three course S-1 plus Paclitaxel (S-1[80mg/day] between day 1 and 14, and Paclitaxel [50mg/m2] on day 1 and 8, followed by 7 days rest) is administered before surgery.. Surgical operation is performed 21-35 days after chemotherapy.
Fourteen to fifty-six days after surgical operation, a three course of Paclitaxel ( 50mg/m2 on day 1 and 8, followed by 14 days rest) is administered followed by a eight course of S-1 (80mg/day between day 1 and 14 followed by 7 days rest).
20 | years-old | <= |
75 | years-old | >= |
Male and Female
1.histologically proven gastric cancer
2.type 4 gastric cancer
3.N0-2 (not bulky)
4.curative resection A or B in the preoperative diagnosis,
5.Thracotomy is not necessary
6.PS 0-1 in ECOG
7.Age: 20-75 yo
8.No history of prior surgery or chemotherapy for cancer
9.No obvious bleeding from lesion or no obstruction of intestine
10.sufficient oral intake
11.No organ failure detected by blood examination
12.CCr is over 50ml/min in Cockcroft-Gault method
13.No severe complications or no active double cancer except resected cancer in situ
14.written informed consent
1.patients with severe diseases (non-treated ischemic cardiac disease, arrhythmia, liver cirrhosis, nterstitial pneumonia, fresh bleeding which needs transfusion, mental disorder, uncontrolled DM, intestinal obstruction, etc.)
2.febrile infection
3.allergy against polyoxyethylene-castor oil
4.under pregnancy or nursing
5.receiving steroids
6.receiving flucytosine, phenytoin or warfarin
7.doctors' decision
31
1st name | |
Middle name | |
Last name | Fujitani Kazumasa |
National Hospital Orgamnzation
Osaka Medical Center
Dpt.Surgery
2-1-14 2-1-14.Houenzaka, chuo-ku, Osaka, 540-0006
06-6942-1331
1st name | |
Middle name | |
Last name | Furukawa Hiroshi |
Sakai City Hospital
Director
1-1-1,Minamiyasuicho,Sakai-ku,Sakai, 590-0064
072-221-1700
OGSG
NPO Osaka Chinical Study Supporting Organization
Self funding
NO
2007 | Year | 04 | Month | 23 | Day |
Unpublished
Terminated
2005 | Year | 03 | Month | 14 | Day |
2005 | Year | 04 | Month | 01 | Day |
2009 | Year | 03 | Month | 01 | Day |
2009 | Year | 03 | Month | 01 | Day |
2009 | Year | 03 | Month | 01 | Day |
2009 | Year | 03 | Month | 01 | Day |
2007 | Year | 04 | Month | 19 | Day |
2021 | Year | 11 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000823